Skip to content

Clinical Evaluation of Toric Intraocular Lens Made by Aurolab

Clinical Evaluation of Toric Intraocular Lens Made by Aurolab

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01396616
Acronym
TORICIOL
Enrollment
120
Registered
2011-07-19
Start date
2011-08-31
Completion date
2013-06-30
Last updated
2013-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism

Brief summary

The purpose of this study is to measure visual acuity and Intraocular Lens (IOL) rotational stability after implantation of TORIC IOL and to assess the post operative complications after implantation of TORIC IOL.

Detailed description

Among available methods for treating astigmatism in cataract surgery, the implantation of toric IOLs is an emerging technology that shows promising results. Similar to implanting a one-piece acrylic lens, toric IOLs provide good distance vision and, in many patients, freedom from spectacles for distance vision. A low absolute residual refractive cylinder has been associated with the implantation of toric IOLs, and the safety profile for toric IOLs has been good. As improvements with regard to rotational stability and treatment and cylinder power range are made, toric IOLs will emerge as an effective, safe treatment option for correcting astigmatism during cataract surgery. Further, to evidence on the safety and efficacy of TORIC IOL for patients having cataract associated with astigmatism served as the basis for us to identify the published literature on the safety and efficacy of TORIC IOL implantation in the treatment of cataract associated with astigmatism, thus provide a background for the development of clinical investigation plan for the present study.

Interventions

DEVICEExperimental - Toric Intraocular lenses

Toric Intraocular Lenses will be implenated with cataract patients having astigmatism

Sponsors

Aurolab
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 40 to 65 * Senile cataract * Posterior Sub Capsular Cataract (PSCC) * Astigmatism 1.25 D or more * Residence within 100 kms of Madurai

Exclusion criteria

* Traumatic & Complicated cataract * Poor mydriasis * Amblyopia * Severe Pseudo exfoliation (PXF) * Dense posterior polar cataract (PPC) * One eyed patients * Uveitis * Corneal pathology / Scar * Retinal Pathology contributing to visual loss * Intraoperative complication like PC rupture, Zonular dialysis

Design outcomes

Primary

MeasureTime frameDescription
vision improvement150 daysThe visual acuity will be measured after iol implantation on 1 day, 10 days, 40 days and 150 days post operatively

Secondary

MeasureTime frameDescription
Refractive error correction150 daysTo measure the refraction error after IOL implantation on 1 day, 10 days, 40 days and 150 days post operatively

Countries

India

Contacts

Primary ContactDr. Haripriya Aravind, MBBS., MS.,
haripriya@aravind.org+91 452 4356100
Backup ContactMr. Mohamed Hussain, M.Pharm
clinicalresearch@aravind.org+91 452 4356100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026